ClinicalTrials.gg

Program

sotevtamab

Also written as “Sotevtamab” and “AB-16B5”.

Its studies are mostly in Pancreatic Neoplasms · Carcinoma, Non-Small-Cell Lung · Colorectal Neoplasms · Neoplasm Metastasis, led by 2 companies.

Furthest: phase 2, since Apr 23, 20204 company-led studies, 1 open or running

Who develops it

Each company that leads studies of it, as its sponsor page counts them.

CompanyStudies it leadsFurthest phaseFirst studyNext primary completion
Alethia Biotherapeutics31 open or runningphase 2since Apr 23, 2020Mar 30, 2015none ahead
ImmunityBio10 open or runningphase 1since Nov 20, 2025Nov 20, 2025none ahead

How these companies relate is not in the registry. A license or acquisition is shown only with a dated source, such as a company release or filing.

History and what’s ahead

From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.

  1. Mar 30, 2015First study: phase 1 study in Neoplasm MetastasisNew to Alethia BiotherapeuticsAlethia Biotherapeutics · NCT02412462 · 15 enrolled · Canada
  2. Apr 23, 2020Phase 2 study in Carcinoma, Non-Small-Cell LungAlethia Biotherapeutics · NCT04364620 · 35 enrolled · United States, Canada
  3. Nov 17, 2023Phase 2 study in Colorectal NeoplasmsAlethia Biotherapeutics · NCT06225843 · 17 planned · Canada
  4. Nov 20, 2025ImmunityBio's first study: phase 1 study in Pancreatic NeoplasmsNew to ImmunityBioImmunityBio · NCT07488884

TargetBeta

Not stated by its company or a source we have read. Most early programs say nothing of it.

Studies

All 4 led by companies developing it, newest first. Each opens its study page.

StudyPhaseStatusLed byPrimary completionSize
NCT07488884Pancreatic Neoplasms1WithdrawnImmunityBioJun 1, 20270
NCT06225843Colorectal Neoplasms · Canada2RecruitingAlethia BiotherapeuticsMar 202617
NCT04364620Carcinoma, Non-Small-Cell Lung · United States, Canada2CompletedAlethia BiotherapeuticsDec 31, 202335
NCT02412462Neoplasm Metastasis · Canada1CompletedAlethia BiotherapeuticsJan 201715

How it is read

Names in the registry

  • “Sotevtamab”, 2 entries
  • “AB-16B5”, 2 entries

Conditions, from the studies’ own filings

First seen by our ledger Nov 13, 2026.

What this can’t show

  • Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
  • Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
  • Primary completion dates are the sponsors’ estimates and often move.
  • A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.